Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma.
Abstract 569: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial (00:58-01:35)
GMMG phase III trial ReLApsE (01:35-03:03)
Abstract 4559: Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study (03:03-03:40)
Disclosures: Shaji Kumar discloses research funding for clinical trials to the institution from: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio and Molecular Templates; Consulting/Advisory Board participation (with no personal payments) from: Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium and (with personal payment) Oncopeptides, Beigene, Antengene and GLH Pharma.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Share this Video
Related Videos In Multiple Myeloma
Binod Dhakal, ASCO 2023: The CARTITUDE-4 trial, ciltacabtagene autoleucel for patients with lenalidomide-refractory multiple myeloma
Lenalidomide is a standard of care in multiple myeloma. But with the prevalence of the lenalidomide-refractory population increasing, the CARTITUDE-4 trial aimed to assess ciltacabtagene autoleucel for this patient population. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to discuss the mechanism of action of ciltacabtagene […]
Binod Dhakal, ASCO 2023: The treatment paradigm for multiple myeloma
The treatment paradigm for patients with multiple myeloma is very complex. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to break down the treatment paradigm in multiple myeloma, discussing how to handle different patient cases. The abstract entitled ‘First phase 3 results from CARTITUDE-4: Cilta-cel versus […]
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!